Moxetumomab pasudotox as re-treatment for heavily-pretreated relapsed hairy cell leukemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Moxetumomab pasudotox as re-treatment for heavily-pretreated relapsed hairy cell leukemia

Published:2021-05-25 Issue:11 Volume:62 Page:2812-2814
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Yurkiewicz Ilana R.¹^ORCID,Coutre Steve¹,Ghesquieres Herve²,Pastan Ira³,Kreitman Robert J.³

Affiliation:

1. Division of Hematology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA

2. Department of Hematology, Hôpital Lyon Sud, Université Claude Bernard Lyon 1, Pierre Bénite, France

3. Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2021.1929959

Reference9 articles.

1. Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox

2. Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia

3. Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up

4. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

5. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hairy cell leukemia 2024: Update on diagnosis, risk‐stratification, and treatment—Annual updates in hematological malignancies;American Journal of Hematology;2024-03-05

2. Immunotherapy;Medicines for Cancer;2023

3. A Frail Hairy Cell Leukemia Patient Successfully Treated with Pegylated Interferon-α-2A;Journal of Clinical Medicine;2022-12-27

4. Hairy Cell Leukemia;Leukemia;2022-10-16

5. Intraductal administration of transferrin receptor-targeted immunotoxin clears ductal carcinoma in situ in mouse models of breast cancer—a preclinical study;Proceedings of the National Academy of Sciences;2022-06-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3